Insider · CIK 0001872422
Sundaram Preethi
officer
Files at CPRX (CATALYST PHARMACEUTICALS, INC.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 27, 2024 | CPRX CATALYST PHARMACEUTICALS, INC. | MOption exercise Common Stock, par value $0.001 per share | +6,667 | - | - | 36,648 | Dec 31, 2024 |
| Dec 27, 2024 | CPRX CATALYST PHARMACEUTICALS, INC. | FTax withholding Common Stock, par value $0.001 per share | -2,345 | - | - | 34,303 | Dec 31, 2024 |
| Dec 27, 2024 | CPRX CATALYST PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -6,667 | $0.00 | $0 | 695,099 | Dec 31, 2024 |
| Dec 9, 2024 | CPRX CATALYST PHARMACEUTICALS, INC. | MOption exercise Common Stock, par value $0.001 per share | +6,855 | - | - | 32,396 | Dec 11, 2024 |
| Dec 9, 2024 | CPRX CATALYST PHARMACEUTICALS, INC. | FTax withholding Common Stock, par value $0.001 per share | -2,415 | - | - | 29,981 | Dec 11, 2024 |
| Dec 9, 2024 | CPRX CATALYST PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -6,855 | $0.00 | $0 | 701,766 | Dec 11, 2024 |
| Nov 21, 2024 | CPRX CATALYST PHARMACEUTICALS, INC. | AGrant or award Options to purchase common stockderivative | +137,553 | $0.00 | $0 | 691,812 | Nov 25, 2024 |
| Nov 21, 2024 | CPRX CATALYST PHARMACEUTICALS, INC. | AGrant or award Options to purchase common stockderivative | +16,809 | $0.00 | $0 | 708,621 | Nov 25, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.